Investment Income and NII Delivered
Generated total investment income of $30.0M and net investment income (NII) of $11.6M in the fourth quarter, delivering $0.32 of NII per share and maintaining a base dividend of $0.33 per share with approximately $0.65 per share of spillover income at year-end.
Active Origination and Portfolio Additions
Completed seven investments in Q4 totaling $42.9M across technology, health care, and select consumer sectors (including a $20M mobility deal, $10M consumer SPV, $20M commitment to Shield Therapeutics with $2M funded at close, and $10.9M of follow-ons to existing portfolio companies).
SWK Acquisition Expected to Drive Diversification and Accretion
Announced acquisition of SWK Holdings expected to close in early April; SWK bring ~13 loans (~$235M fair value), equity positions and royalties, and will increase health care and life sciences exposure. Management expects run-rate NII accretion in the mid-single digits, modest ROE expansion, improved dividend coverage, and reduced average position size to $23.5M (2.2% of portfolio) from $30.3M (3.1%), a ~22% reduction in average position size.
Strong Liquidity and Financing Flexibility
Available liquidity of $395.2M as of 12/31/2025 (including borrowing capacity of $377M) and launched an underwritten public offering of $103.25M unsecured notes due Feb 2031 at 7.25%, while redeeming higher-coupon near-term notes to extend the debt maturity ladder and lower cost of funds.
Conservative Credit Profile and Low Nonaccruals
Portfolio remains almost exclusively first-lien senior secured loans with only one loan on nonaccrual (Domingo Healthcare) with a cost basis of $4.8M and fair value of $2.4M (50% of cost), representing just 0.25% of the total investment portfolio at fair value.
Operating Efficiency and Loss Reduction
Total operating expenses decreased to $18.4M from $21.0M (-12.4%), and net realized losses on investments improved to $0.377M from $1.3M (approximately -71%), showing tighter expense control and fewer realized losses.
Stable NAV, Modest Asset Base Contraction
Net assets of $484.9M and NAV per share of $13.42 as of 12/31/2025, a modest NAV decline of ~1% from $13.55. Total investment portfolio fair value was $927.4M, down 2% from $946.0M year-over-year.
Pipeline Momentum and Sourcing Benefits from BC Partners
Management reported a stronger origination pipeline year-over-year, citing greater deal flow and enhanced sourcing from BC Partners and expected additive sourcing from SWK, with measured optimism for 2026 despite seasonal Q1 cadence.